Former cancer researcher turned CEO, Emil Kendziorra, discusses advancements in medical biostasis and cryomedicine. Topics include cryopreservation, life insurance, biostasis methods, challenges in cryopreservation, and warming technology research. Special offer for listeners interested in becoming members of Tomorrow Bio.
Dr. Emil Kensiora emphasizes the need for advancements in cryomedicine to accelerate the preservation of human bodies for future revival.
Cryopreservation offers a more immediate solution compared to longevity pills, with the potential for significant impact due to its smaller scale and focused contributions.
Deep dives
Dr. Emil Kensiora's Diverse Career Background and Transition to Cryopreservation Focus
Dr. Emil Kensiora, a summa cum laude graduate, shifted from cancer research to entrepreneurship after noticing the slow progress in life extension studies. He founded tech and medical companies before devoting his efforts to medical biostasis and cryomedicine at Tomorrow Bio and the European Biostasis Foundation. This shift aimed to accelerate advancements in preserving human bodies for future revival.
Cryopreservation's Position as a Current Reality Over Longevity Pills
The decision to venture into cryopreservation over other longevity methods was influenced by its immediacy and engineering focus. Cryopreservation presents a current solution compared to the elusive promise of longevity pills. Dr. Kensiora emphasizes the field's impact potential due to its smaller scale, making each contribution more pronounced than in mainstream longevity research.
Advancements in Cryopreservation Techniques for Enhanced Quality and Viability
Organizations like Tomorrow Bio aim to improve the quality of cryopreservation by achieving a consistent high standard. Research focuses on technologies like nanorewarming, microwaving, and high-frequency ultrasound for uniform warming of large human volumes. This pursuit aims to close the quality gap between different cryopreservation outcomes and elevate the overall success rates.
Membership Benefits, Research Funding, and Future Prospects in Biostasis
Tomorrow Bio's membership fees primarily support standby teams and operational costs. Extra funds may contribute to research and technology enhancement. Dr. Kensiora notes that members' contributions bolster the organization's readiness and research efforts. Additionally, the establishment anticipates broadening its impact and evolving the biostasis field in the coming years.
Our guest in this episode is Dr. Emil Kendziorra. Emil graduated summa cum laude, which means, with the highest honours, from the University of Göttingen in Germany, having previously studied at the University of Pécs in Hungary. For several years, he then devoted himself to cancer research with the hope of contributing to longevity science. After realizing how slowly life-extension research was progressing, he pivoted into entrepreneurship. He has been CEO of multiple tech and medical companies, most recently as a Founder and CEO of Medlanes and onFeedback, which were sold, respectively, to Zava and QuestionPro.
Emil then decided to dedicate the next decades of his life, he says, to advancing medical biostasis and cryomedicine. He is currently the CEO of Tomorrow Bio and the President of the Board at the European Biostasis Foundation.
A special offer:
Thanks to Tomorrow Bio, an offer has been created, exclusively for listeners to the London Futurists Podcast who decide to become members of Tomorrow Bio after listening to this episode. When signing up online, use the code mentioned toward the end of the episode to reduce the cost of monthly or annual subscriptions by 30%.
Small print: This offer doesn’t apply to lifetime subscriptions, and is only available to new members of Tomorrow Bio. Importantly, this offer will expire on 15 September 2024, so don’t delay if you want to take advantage of it.